FDA accepts for priority review sBLA for Opdivo (nivolumab) for patients with mUC
Bristol-Myers Squibb announced the FDA accepted a sBLA, which seeks to expand use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma that has progressed on or after platinum-containing therapy. October 21, 2016